B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
IBRX
ImmunityBioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-04-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+60.7
Score
AI commentary
The setup has improved from a pure survival story into a monitored commercial execution story, but it is still not clean enough for a high-conviction bullish call. Primary-source evidence supports real revenue momentum and added liquidity, yet the financing structure, ongoing balance-sheet pressure, and need for formal 10-Q confirmation keep the thesis in cautious watch mode.
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15eventQ1 2026 10-Q needs to reconcile preliminary revenue and liquidity figuresHigh impact
The April 9, 2026 8-K furnished preliminary Q1 2026 net product revenue of about $44.2 million and cash, cash equivalents, and marketable securities of about $380.9 million, with explicit warning that final 10-Q figures may differ; the formal Q1 filing is the next hard checkpoint for revenue quality, cash use, and any updated outlook [#8-K-2026-04-09].
2026-05-15eventMarch financing amendment improves cash but raises the revenue-interest burdenHigh impact
The March 30, 2026 8-K says ImmunityBio received $75.0 million gross under a second amendment to its Revenue Interest Purchase Agreement, but the purchaser revenue share stepped up to a tiered 5.625% to 12.50% of covered-territory net sales from 4.5% to 10.0%; investors still need cleaner disclosure on the net runway benefit versus the added claim on future ANKTIVA sales [#8-K-2026-03-30].
2026-12-31catalystANKTIVA commercial adoption and bladder-cancer label expansion remain the core upsideHigh impact
Primary company materials point to continued ANKTIVA commercialization momentum: the April 9 exhibit cited 168% year-over-year Q1 unit growth, March 2026 NCCN guideline inclusion for papillary-only disease, and five approved or authorized regulatory jurisdictions, while the 10-K showed about $113 million of 2025 net product revenue; if these trends persist and the fully enrolled QUILT-2.005 program stays on track for a 2026 supplemental BLA, the equity can re-rate, but proof still depends on repeatable execution and regulatory follow-through [#8-K-2026-04-09] [#10-K-2026-02-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology